Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study
Open Access
- 20 October 2015
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 38 (12) , 2250-2257
Abstract
OBJECTIVE: This study investigated the efficacy and safety of once-daily liraglutide 1.2 mg versus placebo as add-on to insulin treatment in normal-weight patients with poorly controlled type 1 diabetes. RESEARCH DESIGN AND METHODS: In a randomized (1:1), double-blind, placebo-controlled design, 40 patients with type 1 diabetes (HbA1c ≥8% [64 mmol/mol]) received once-daily liraglutide 1.2 mg or placebo for 12 weeks. Continuous glucose monitoring was performed before and at the end of treatment. The primary end point was change in HbA1c. Secondary end points included change in insulin dose, weight, glycemic excursions, heart rate, and blood pressure. RESULTS: Baseline HbA1c was similar in the liraglutide and placebo group (8.8 ± 0.2 and 8.7 ± 0.1% [72.5 ± 2.2 and 71.8 ± 1.5 mmol/mol]). Change in HbA1c from baseline was −0.6 ± 0.2% (−6.22 ± 1.71 mmol/mol) with liraglutide and −0.5 ± 0.2% (−5.56 ± 1.67 mmol/mol) with placebo (P = 0.62). Variation in glycemic excursions did not change in either group. Change in body weight was −3.13 ± 0.58 and +1.12 ± 0.42 kg (P < 0.0001) with liraglutide and placebo, respectively. The bolus insulin dose decreased in liraglutide-treated patients and did not change with placebo treatment (4.0 ± 1.3 vs. 0.0 ± 1.0 IU, P = 0.02). Heart rate increased within the liraglutide group (P = 0.04) but not compared with placebo, whereas mean systolic blood pressure decreased compared with placebo (between-group difference 3.21 mmHg [95% CI −8.31 to 1.90], P = 0.04). Liraglutide was more frequently associated with gastrointestinal adverse effects. The incidence of hypoglycemia did not differ between groups. CONCLUSIONS: Liraglutide significantly reduces body weight and insulin requirements but has no additional effect on HbA1c in normal-weight patients with type 1 diabetes inadequately controlled on insulin alone.Keywords
Funding Information
- The Danish School of Metabolism and Endocrinology
- Novo Nordisk Foundation, Center for Basic Metabolic Research
- The Research Foundation at Hvidovre University Hospital
- The Beckett Foundation,
- Novo Nordisk A/S
This publication has 42 references indexed in Scilit:
- Incretin hormones and the satiation signalInternational Journal of Obesity, 2013
- Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesityCardiovascular Diabetology, 2012
- Normal Reference Range for Mean Tissue Glucose and Glycemic Variability Derived from Continuous Glucose Monitoring for Subjects Without Diabetes in Different Ethnic GroupsDiabetes Technology & Therapeutics, 2011
- Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell FunctionDiabetes Care, 2011
- Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell FunctionDiabetes, 2011
- Effects of Exenatide Alone and in Combination With Daclizumab on β-Cell Function in Long-Standing Type 1 DiabetesDiabetes Care, 2009
- Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group.Diabetes Care, 1999
- Adverse Events and Their Association With Treatment Regimens in the Diabetes Control and Complications TrialDiabetes Care, 1995
- Reduced Awareness of Hypoglycemia in Adults With IDDM: A prospective study of hypoglycemic frequency and associated symptomsDiabetes Care, 1995
- Frequency of Severe Hypoglycemia in Patients With Type I Diabetes With Impaired Awareness of HypoglycemiaDiabetes Care, 1994